Drug company GlaxoSmithKline has told Canadian doctors to stop using one lot of its H1N1 vaccine until an investigation into a higher-than-expected number of severe allergic reactions is completed. The U.S. vaccine will not be identical to Arepanrix, the GSK H1N1 vaccine used in Canada. Arepanrix contains an adjuvant, a substance designed to boost the immune response, but adjuvants have never been approved for use in U.S. flu vaccines. Almost all of the 172,000 doses in question, distributed the week of Nov. 2 to six Canadian provinces, already have been administered, said Geoffrey Matthews, a spokeswoman for the Public Health Agency of Canada, which, with GSK and Health Canada, is investigating cases of anaphylaxis. Symptoms of anaphylaxis include trouble breathing, chest tightness and swelling of the mouth and throat. Six cases have been reported, Matthews says. In the USA, the Vaccine Adverse Event Reporting System said that as of Nov. 13 it had received 116 reports of serious health events related to the vaccine, including eight deaths - similar to the number in previous years after a similar number of seasonal flu vaccine doses had been shipped.
Latest
Latest News
Each news summary is created according to strict standards. Here's how we do it.
Each summary is created using a consistent editorial procedure. The target length is approximately 16 lines of 11-point Arial text in a 650-pixel-wide column. Up to 25% of a summary may be set in bold to emphasize the most important ideas. Summaries are composed of verbatim excerpts presented in the same sequence as they appear in the original news source, with very minor editorial additions. Where material has been omitted between excerpts, the omission is indicated with ellipses (...). Any words added by an editor for clarity or context appear in [brackets]. Our original news editor was Fred Burks. Tod Fletcher edited most summaries from 2007 through 2014, and Mark Bailey has served as news editor since 2014.